Introduction

Diabetes mellitus (DM) is the commonest metabolic disease currently affecting more than 250 million people worldwide and it costs the Governments of the world more than £800 billion to diagnose, treat and care for diabetic patients. DM is associated with numerous long-term complications including cardiomyopathy, nephropathy, neuropathy and retinopathy. This review addresses diabetic painful neuropathy (DPN) which is one of the well-known complications of diabetes and it affects up to 53% of diabetic population [1]. It is the most common form of painful neuropathy [2]. It manifests with varying description from mild pins and needle sensation to the stabbing pain, burning, unremitting or even described as electric shock. The most common feature is cutaneous hypersensitivity leading to acute distress on contact with an external stimulus, such as clothing [3]. The pathogenesis of DPN is mainly caused by inflammatory process [4] and strongly correlates with longer duration of the diabetes and poor glycaemic control [5-18].

Treatment induces acute neuropathy due to rapid glycaemic control has been reported in literature as ‘insulin neuritis’ that usually manifests with severe excruciating neuropathic pain in the first month of initiation of insulin or oral hypoglycaemic agents. Symptoms usually last up to 6 months and respond to treatment that is usually needed up to 6 months [3]. Insulin neuritis was first described by Caravati [19] in 1933. He reported a diabetic woman with numbness, tingling, and shooting pains in the lower extremities that appeared four weeks after the initiation of insulin. The pain increased despite the use of analgesics and sedatives, but resolved within 3 days of stopping insulin concurrent with severe hyperglycaemia. Further attempts at the use of insulin resulted in similar levels of pain. He called the condition “insulin neuritis” [19]. The word insulin neuritis is a misnomer, as it can also be induced by oral hypoglycaemic agent [20]. The cause is not directly by insulin but mainly due to the change in flux of blood glucose caused by
rapid change in blood glucose level following pharmacological treatment [21].

**Symptoms**

There are several studies and case reports in the literature about insulin neuritis with varying presentation after starting insulin or oral hypoglycaemic agents. These reports described the most common features as generalized pain bilaterally mainly distally in feet with burning sensation, hypersensitivity and contact discomfort of the skin within 2 to 4 weeks [20,22,23]. It may present with truncal neuropathy [24-27], autonomic neuropathy [28], worsening of retinopathy [29], and even with profound weight loss [22,30-32].

**Generalize pain mainly distally**

The most common presentation of Insulin neuritis is symmetrical and bilateral distal neuropathic pain mainly involving feet [3]. In one observational study on 6 patients with diabetes, all experienced severe excruciating bilateral neuropathic pain mainly in feet after 2-4 weeks of insulin treatment with rapid reduction of blood glucose up to one fifth of initial levels. This improved in all cases with symptomatic treatment allowing discontinuation of therapy in 3-8 months [20]. A case report on a newly diagnosed type 1 diabetes patient described development of severe pain in his feet, which prevented him from walking, after initiation of insulin. The HbA1c of that patient dropped from 14.1 to 7.6%, and 3 months after presentation, the patient showed dramatic improvement and regained his ability to walk [33]. There is another similar case report of painful neuropathy on 15th day of treatment with insulin or oral hypoglycaemic agents. These reports described about insulin neuritis with varying presentation after starting insulin or oral hypoglycaemic agents. These reports described the most common features as generalized pain bilaterally mainly distally in feet with burning sensation, hypersensitivity and contact discomfort of the skin within 2 to 4 weeks [20,22,23]. It may present with truncal neuropathy [24-27], autonomic neuropathy [28], worsening of retinopathy [29], and even with profound weight loss [22,30-32].

**Diabetic neuropathic cachexia**

Painful neuropathy is sometimes associated with profound weight loss and called “Diabetic neuropathic cachexia”. This has also been reported with insulin neuritis that could last up to a year. The exact mechanism and cause is unknown [3]. It is observed that constant pain and discomfort can cause loss of appetite and low mood which results in patients not eating enough and start losing weight. Most patients respond well with neuropathic pain treatment which gives pain relief and regain weight. In one observational study, 9 diabetic patients experienced painful neuropathy with constant burning pain mainly in the legs, especially distally. There was marked troublesome allodynia associated with profound weight loss along with depression with impotence. These severe manifestations subsided in most cases in 6 months and in all cases in 10 months [22]. There is another case report in which patient presented with painful neuropathy, profound weight loss after initiation of insulin therapy within 3 months [31].

**Truncal neuropathy**

Insulin neuritis may precipitate focal neuropathic pain called “Truncal neuropathy” on specific dermatome region. Truncal neuropathy in diabetes presents with neuropathic pain such as a hypoesthesia, regional hyperalgesia, allodynia and sometime focal weakness in specific dermatome region. It usually presents with unilateral abdominal or thoracic wall pain [3,25]. There was one case of insulin neuritis which presented with painful neuropathy with paraesthesia and hyperesthesia restricted to the abdomen and this was associated with profound weight loss. The haemoglobin A (1c) had dropped from 12% to 7.5% within 5 months, following rapid improvement in glycaemic control. On investigation, there was no indication of disease in intra-abdominal area. The symptoms improved dramatically within 4 months after symptomatic treatment [30].

It is not uncommon that these patients have to undergo a number of investigations to determine the cause of pain before having the diagnosis of truncal neuropathy [24-27,30]. There are several cases of truncal neuropathy that were misdiagnosed initially as for example hernia due to focal weakness on abdominal wall [26], angina due to left sided chest wall pain [25] and painless gall stones due to focal sensory deficit complicated with painless jaundice secondary gall stone [27]. The diagnosis of truncal neuropathy is essentially clinical and positive recognition of neuropathic element of pain is the key factor. Most people respond well on neuropathic treatment and usually settle in 3 to 12 months.

**Autonomic neuropathy**

Autonomic dysfunction is one of the complications of diabetes3. It manifests with one or more of the following: erectile dysfunction, gastroparesis, neurogenic bladder, dry feet, depressed cough reflex, postural hypotension or high blood flow to foot [35,36]. Insulin neuritis has been reported to precipitate autonomic neuropathy. In one prospective study on 16 diabetic patients followed up for 18 months, all the patients develop severe painful neuropathy in 8 weeks of intense glycaemic treatment. All individuals with treatment for induced neuropathy had evidence of autonomic dysfunction on testing and exhibited symptoms of autonomic impairment. Approximately, 69% of cohort had systolic blood pressure falls > 20 mmHg. Symptoms of autonomic dysfunction were more prevalent and more severe in subjects with type 1 diabetes, particularly with respect to symptoms of orthostatic intolerance and gastrointestinal function. Urinary frequency, nocturia and anhidrosis were reported more frequently in individuals with type 2 diabetes [28].

**Retinopathy**

Retinopathy is a well-known complication of diabetes and directly related with poor glycaemia and duration of diabetes.
Pathogenesis

In 1992 Boulton first described the observation that acute painful neuropathy might follow sudden change in glycaemia control suggesting that blood glucose flux could precipitate pain. Sudden changes in glycaemia may contribute to the generation of impulses or even induce relative hypoxia in nerve fibres, indicating that it is the combination of structural and functional changes in peripheral nerves which cause the pain [21]. This observation was experimentally tested by Kihara et al. [41] in 1994 on rats. In their study, they infused insulin under non-hypoglycaemic conditions and evaluated its effect on endoneurial oxygen tension, nerve blood flow, and the oxy-haemoglobin dissociation curve of peripheral nerves in normal and diabetic rats. Their results showed that insulin administration could cause a reduction in nerve nutritive blood flow and an increase in arterio-venous shunt flow. When the latter was eliminated by the closure of arterio-venous shunts (infusion of 5-hydroxytryptamine), endoneurial oxygen reverted to normal. These findings clearly indicate a deleterious vasoactive effect of insulin and may explain the development of insulin neuritis [41].

In 1996 Tesfaye et al observed neurovascular changes in vivo in five human diabetic patients with insulin neuritis. These patients presented with severe sensory symptoms but clinical examination and electrophysiological tests were normal except with one subject who had severe autonomic neuropathy and all tests were abnormal. On sural nerve exposure in vivo, epineural blood vessels showed severe structural abnormalities resembling the retinopathy changes normally seen in the retina, including arteriolar attenuation, tortuosity and arterio-venous shunting and proliferating new vessels formation. They hypothesized that the structural abnormalities with new vessels formation in epineural blood vessels cause steal effect and hence results in hypoxia and neuropathic pain [39]. It can now be postulated that sudden change in glycaemic control can cause flux effect resulting in structural and functional changes at the epineural blood vessels of nerves which in turn can lead to neuropathic pain “Insulin neuritis (Figure 1)” [21,39].

Treatment

Management of neuropathic pain in “insulin neuritis” is symptomatic including first line medication tricyclic antidepressants (Amitriptyline) or selective serotonin uptake inhibitor (Duloxetine). Second line medications include anti-epileptic medications (Gabapentin, Pregabalin, Carbamazepine and Topiramate) and Opioids. Most patients recover within 6 months of onset of insulin neuritis [3].

Conclusion

The flow diagram in Figure 2 summarises the pathogenesis of insulin neuritis. With increasing prevalence of diabetes and its complications, both health professional and patients are keen to have good glycaemic control in order to prevent long term
complications [42]. Most of the time it is not a problem but on several occasions intense treatment for rapid glycaemic control may cause insulin neuritis. This is presumed to be caused by change in glucose flux which can result in structural and functional changes at the nerves leading to hypoxia. This in turn can precipitate neuropathic pain and the whole phenomenon is called “insulin neuritis”. It usually manifests distally in feet and is bilateral with burning sensation, hypersensitivity and allodynia. It could affect focally - truncal neuritis and may present with neuropathic pain and/or weakness in dermatomal region. Similarly, it may present with autonomic symptoms. Constant pain may cause cachexia and loss of appetite which can result in significant weight loss. Most patients respond well with neuropathic treatment and recover within 6 months. It is very important to be aware that treatment induced insulin neuritis can have significant impact on the quality of the life of the diabetic patient. This can be easily prevented by gradual glycaemic control and by symptomatic treatment as necessary. Healthcare professionals need to be aware of this condition when managing poorly controlled diabetic patients and should consider gradual titration of the pharmacological agents employed to treat the patients.

References


This work is licensed under Creative Commons Attribution 4.0 License
DOI: 10.19080/OAJNN.2018.09.555759

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php

How to cite this article: Amir Aslam, Satyan Rajbhandari, Jaipaul Singh. Diagnosis and Treatment of a Typical Painful Neuropathy Due to “Insulin Neuritis” in Patients with Diabetes. Open Access J Neurol Neurosurg. 2018; 9(2): 555759. DOI: 10.19080/OAJNN.2018.09.555759.